TransCode Therapeutics receives patent approvals in Australia and Japan

Go back to TransCode Therapeutics receives patent approvals in Australia and Japan

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

September 22, 2026 8:04 AM EDT

Allowances of Patent Applications in Australia and Japan support differentiated RNA platform for targeted cancer therapy and immune modulation

BOSTON, Sept. 22, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements in its global intellectual property portfolio, highlighted by (i)... More